AGIMM (acronym of AIRC-Gruppo Italiano Malattie Mieloproliferative) represents a group of italian scientists who, thanks to AIRC 5 per 1000 fundings , joined together in a research programme focused on "classic" chronic myeloproliferative neoplasms. These disorders, which are characterized by the involvement of a multipotent stem cell of the bone marrow, include: Polycythemia Vera, Essential Thrombocytemia, Primary Myelofibrosis and Secondary Myelofibrosis following Polycythemia Vera or Essential Thrombocytemia. During the last years significant progresses have been made in basic and applied research in these disorders which, in 2005, led to the identification of the first recurrent molecular abnormality, the JAK2 V617F point mutation. Continue...
- Department of Critical Medical and Surgical Care, Section of Hematology, University of Florence, coordinated by Alessandro M. Vannucchi (go to Unit page)
- Unit of Clincal Epidemiology/Center for the Study of Myelofibrosis. IRCCS Policlinico S. Matteo Foundation, Pavia, coordinated by Giovanni Barosi (go to Unit page)
- Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation and University of Pavia, coordinated by Mario Cazzola (go to Unit page)
- IFOM-FIRC Institute of Molecular Oncology Foundation, Milan, coordinated by Elisabetta Dejana (go to Unit page)
- Hematology Unit, Ospedali Riuniti di Bergamo, coordinated by Alessandro Rambaldi (go to Unit page)
- Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, coordinated by Rossella Manfredini (go to Unit page)